Chaitram Jasmine M, Jevitt Laura A, Lary Sara, Tenover Fred C
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
J Clin Microbiol. 2003 Jun;41(6):2372-7. doi: 10.1128/JCM.41.6.2372-2377.2003.
A total of 150 laboratories in 33 countries that followed the NCCLS testing procedures participated in the World Health Organization's External Quality Assurance System for Antimicrobial Susceptibility Testing (EQAS-AST) from January 1998 through March 2001. Laboratories tested seven bacterial isolates for antimicrobial resistance and reported the results to the Centers for Disease Control and Prevention (CDC) in Atlanta, Ga. The results were compared to the results generated at the CDC with the NCCLS broth microdilution and disk diffusion reference methods. Although there were few testing errors with Salmonella enterica subsp. enterica serovar Enteritidis, drugs that are not appropriate for therapy of Salmonella infections were tested and reported by 136 (91%) of 150 laboratories. In addition, 29 (20%) of 150 laboratories used the Staphylococcus aureus breakpoints to report oxacillin results for Staphylococcus saprophyticus. For a vanB-containing Enterococcus faecalis strain, 124 (83%) of 150 laboratories correctly reported vancomycin results that were +/-1 doubling dilution from the reference MIC or +/-3 mm from the reference disk diffusion result. Of the laboratories that tested Streptococcus agalactiae by disk diffusion, 17% reported nonsusceptible results for penicillin in error. While 110 laboratories (73%) tested the S. pneumoniae challenge isolate against a fluoroquinolone, 83% tested it against ciprofloxacin, for which there are no NCCLS interpretive criteria. Ten of 12 laboratories testing levofloxacin and 4 of 4 laboratories testing ofloxacin by an MIC method correctly reported resistant results for the isolate. Feedback letters sent to participating laboratories highlighted areas of susceptibility testing in individual laboratories that needed improvement. The positive impact of the feedback letters and the overall effectiveness of the EQAS program were documented in repeat testing challenges with pneumococci and staphylococci. The 31 and 19% increases in the numbers of laboratories using appropriate testing methods for pneumococci and staphylococci, respectively, in 2000 versus 1998 indicate that laboratory performance is improving.
1998年1月至2001年3月期间,33个国家的150家遵循美国国家临床实验室标准委员会(NCCLS)检测程序的实验室参与了世界卫生组织的抗菌药物敏感性试验外部质量保证系统(EQAS - AST)。各实验室对7株细菌分离株进行了抗菌药物耐药性检测,并将结果报告给位于佐治亚州亚特兰大的疾病控制与预防中心(CDC)。将这些结果与CDC采用NCCLS肉汤微量稀释法和纸片扩散法得出的结果进行比较。虽然肠炎沙门氏菌肠炎亚种肠炎血清型的检测错误很少,但150家实验室中有136家(91%)检测并报告了不适合用于治疗沙门氏菌感染的药物。此外,150家实验室中有29家(20%)使用金黄色葡萄球菌的断点来报告腐生葡萄球菌的苯唑西林结果。对于一株含vanB的粪肠球菌菌株,150家实验室中有124家(83%)正确报告了万古霉素结果,该结果与参考最小抑菌浓度(MIC)相差±1个稀释倍数,或与参考纸片扩散结果相差±3毫米。在通过纸片扩散法检测无乳链球菌的实验室中,17%错误地报告了青霉素不敏感结果。虽然110家实验室(73%)对肺炎链球菌挑战菌株进行了氟喹诺酮类药物检测,但83%的实验室检测的是环丙沙星,而NCCLS没有针对环丙沙星的解释标准。采用MIC法检测左氧氟沙星的12家实验室中有10家,检测氧氟沙星的4家实验室中有4家正确报告了该菌株的耐药结果。发给参与实验室的反馈信突出了各个实验室在药敏试验中需要改进的方面。在对肺炎球菌和葡萄球菌的重复检测挑战中,记录了反馈信的积极影响以及EQAS计划的整体有效性。与1998年相比,2000年分别有31%和19%的实验室采用了适用于肺炎球菌和葡萄球菌的检测方法,这表明实验室的表现正在改善。